Seattle Genetics bags new milestones under Genentech ADC collaboration
This article was originally published in Scrip
Executive Summary
Seattle Genetics has earned undisclosed milestone payments under its antibody-drug conjugate (ADC) collaboration with Roche's Genentech unit after Genentech advanced two ADCs developed with Seattle Genetics' technology into Phase II development.